IA
RXRX icon

IFP Advisors’s Recursion Pharmaceuticals RXRX Stock Holding History

IFP Advisors’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$31.4K Buy
8,554
+899
+12% +$2.99K ﹤0.01% 2692
2026
Q1 		$23.5K Sell
7,655
-22,700
-75% -$87.7K ﹤0.01% 2687
2025
Q4 		$124K Buy
30,355
+20,000
+193% +$99.1K ﹤0.01% 1661
2025
Q3 		$50.5K Buy
10,355
+4,650
+82% +$24.4K ﹤0.01% 2069
2025
Q2 		$28.9K Sell
5,705
-10,103
-64% -$49.6K ﹤0.01% 2345
2025
Q1 		$83.6K Buy
15,808
+3,977
+34% +$29K ﹤0.01% 1625
2024
Q4 		$80K Buy
11,831
+7,455
+170% +$50.1K ﹤0.01% 1583
2024
Q3 		$28.8K Buy
4,376
+2,875
+192% +$20.6K ﹤0.01% 1987
2024
Q2 		$11.3K Buy
1,501
+500
+50% +$4.36K ﹤0.01% 2303
2024
Q1 		$9.98K Buy
1,001
+1,000
+100,000% +$11.1K ﹤0.01% 2234
2023
Q4 		$10 Hold
1
– – ﹤0.01% 3021
2023
Q3 		$8 Buy
+1
New +$10 ﹤0.01% 3274

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

IFP Advisors's RXRX Position: Q2 2026 in Review

IFP Advisors increased its Recursion Pharmaceuticals (RXRX) stake by 12% in Q2 2026, buying an estimated $2.99K and bringing the position to 8,554 shares worth $31.4K. The position accounts for ﹤0.01% of the portfolio, ranked #2692.

IFP Advisors first reported a position in RXRX in Q3 2023 and has held it in 12 quarters since. The position peaked at $124K in Q4 2025. 342 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • IFP Advisors held 8,554 shares of Recursion Pharmaceuticals worth $31.4K as of Q2 2026.
  • IFP Advisors bought 899 Recursion Pharmaceuticals shares in Q2 2026, an estimated $2.99K.
  • Recursion Pharmaceuticals made up ﹤0.01% of IFP Advisors's portfolio in Q2 2026, its #2692 holding.
  • IFP Advisors first reported a position in Recursion Pharmaceuticals in Q3 2023 and has held it in 12 quarters since.
  • IFP Advisors's Recursion Pharmaceuticals position peaked at $124K in Q4 2025.
  • 342 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on IFP Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.